Should You Buy Vor Biopharma Inc (VOR) Today? Analysis, Price Targets, and 2026 Outlook.
Analysis Updated At
2026/01/26
Vor Biopharma Inc (VOR) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock's technical indicators are neutral, insider selling is significantly high, and financial performance shows substantial losses. While analysts generally have a positive outlook on the company's lead drug candidate, the long timeline for meaningful results and reliance on a single asset make it a high-risk investment. Given the user's impatience and unwillingness to wait for optimal entry points, holding off on this stock is advisable.
Technical Analysis
The MACD is above 0 and positively contracting, indicating a potential bullish trend, but the RSI is neutral at 59.858. Moving averages are converging, showing no clear trend. Key support is at 13.502, and resistance is at 17.853. The stock has a 40% chance of declining slightly (-0.71%) in the next day and a 5.09% chance of dropping in the next month.
Analyst Ratings and Price Target Trends
Analysts generally have a positive outlook on the stock, with Buy or Overweight ratings from Citi, TD Cowen, and JPMorgan. However, some firms, like Wedbush, recommend a neutral stance due to the long timeline for global trial data and reliance on a single asset. Price targets range from $9 to $50, with some recent downward adjustments due to share dilution and updated models.
Wall Street analysts forecast VOR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VOR is 38.67 USD with a low forecast of 9 USD and a high forecast of 55 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Wall Street analysts forecast VOR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VOR is 38.67 USD with a low forecast of 9 USD and a high forecast of 55 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Current: 13.740
Current: 13.740
